-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Equal-Weight on Genmab, Lowers Price Target to $56

Benzinga·11/13/2026 17:58:04
Morgan Stanley analyst Judah Frommer maintains Genmab (NASDAQ:GMAB) with a Equal-Weight and lowers the price target from $57 to $56.